Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
DOSULEPIN HYDROCHLORIDE
McDermott Laboratories Ltd t/a Gerard Laboratories
75 Milligram
Film Coated Tablet
1997-09-05
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Dothep 75 mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 75 mg Dosulepin Hydrochloride (Dothiepin Hydrochloride). Excipient: Each tablet contains 115 mg Lactose monohydrate and 1.75 mg Ponceau 4R (E124) For a full list of excipient, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet Red film-coated 8.5 mm normal convex tablets embossed DN/75 on one side and G on the other. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Dothep tablets are indicated in the treatment of symptoms of depressive illness, in particular, where an anti-anxiety effect is required. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Dothep tablets are administered orally. _Recommended dosage schedules:_ _Adults_: Initially 75 mg/day in divided doses (as capsules) or as a single dose at night, increasing to 150 mg/day. In certain circumstances, e.g. in hospital use, dosages up to 225 mg daily have been used. Suggested dosage regimen: 25 to 50 mg three times daily or, alternatively, 75 or 150 mg as a single dose at night. _Elderly_: 50 – 75 mg daily initially. As with any antidepressant, the initial dose should be increased with caution under close supervision. Half the normal adult dose may be sufficient to produce a satisfactory clinical response. _Children_: Not recommended. 4.3 CONTRAINDICATIONS Dothep tablets are contra-indicated in patients with: Closed angle glaucoma, existing urinary retention, recent myocardial infarction, any degree of heart block or other cardiac arrhythmia’s, acute psychoses, severe liver disease, women who are breast-feeding, or patients currently receiving monoamine oxidase inhibitors, or have received these within the previous two weeks. IRISH MEDICINES BOARD ___________ Read the complete document